Zuberi Bader Faiyaz, Zuberi Faisal Faiyaz, Bader Nimrah, Alvi Haris, Salahuddin Javeria
J Pak Med Assoc. 2014 Aug;64(8):896-9.
To compare the efficacy of British Thoracic Society and American Thoracic Society guidelines for reintroduction of anti-tuberculous therapy after drug-induced liver injury, and to assess the ease of administration of each guideline on a scale of 1-10.
The randomised prospective interventional study was conducted at the Department of Medicine and Pulmonology, Dow University of Health Sciences, Karachi, from December 2011 to November 2013. Patients with anti-tuberculous therapy drug-induced liver injury were selected. Hepatotoxic anti-tuberculous therapy was stopped and modified anti-tuberculous therapy was started. Patients were followed weekly till clinical and biochemical parameters got stabilised. After stabilisation, the patients were randomised to one of the two groups to receive re-introduction of anti-tuberculous therapy under the guidelines of British Thoracic Society (Group I) or those of American Thoracic Society (Group II). Means of the groups were analysed by Student's t test and proportions were compared by chi-square test. Multivariate analysis was done for age, body mass index and serum albumin for recurrence of drug-induced liver injury after the re-introduction. P value < 0.05 was taken as significant.
Of the total 325 patients, 163 (50.15%) were in Group I, while 162 (49.84%) were in Group II. The frequency of recurrence of drug-induced liver injury in Group I was 16 (9.8%) and in Group II it was 18 (11.1%).There was no statistically significant difference between the two groups (p < 0.7). Age was positively related with drug-induced liver injury, while body mass index and serum albumin were negatively associated.
There was no significant difference between the two major guidelines though the American Thoracic Society guideline was easier to follow.
比较英国胸科学会和美国胸科学会关于药物性肝损伤后重新引入抗结核治疗的指南的疗效,并以1 - 10分的量表评估每个指南的实施难易程度。
2011年12月至2013年11月在卡拉奇道健康科学大学医学与肺病学系进行了随机前瞻性干预研究。选取抗结核治疗药物性肝损伤患者。停用具有肝毒性的抗结核治疗并开始调整后的抗结核治疗。每周对患者进行随访,直至临床和生化指标稳定。稳定后,将患者随机分为两组之一,在英国胸科学会指南(第一组)或美国胸科学会指南(第二组)指导下重新引入抗结核治疗。通过学生t检验分析两组的均值,通过卡方检验比较比例。对重新引入后药物性肝损伤复发的年龄、体重指数和血清白蛋白进行多变量分析。P值<0.05被视为具有统计学意义。
在总共325例患者中,163例(50.15%)在第一组,162例(49.84%)在第二组。第一组药物性肝损伤复发频率为16例(9.8%),第二组为18例(11.1%)。两组之间无统计学显著差异(p<0.7)。年龄与药物性肝损伤呈正相关,而体重指数和血清白蛋白呈负相关。
尽管美国胸科学会指南更易于遵循,但两大指南之间无显著差异。